サンプル依頼リスト カート
  • English
  • Korean
表紙：血栓溶解薬の世界市場、規模調査＆予測、製品別、適応症別、投与経路別、流通チャネル別、地域別分析、2023～2030年
市場調査レポート
商品コード
1381663

血栓溶解薬の世界市場、規模調査＆予測、製品別、適応症別、投与経路別、流通チャネル別、地域別分析、2023～2030年

Global Clot Busting Drugs Market Size study & Forecast, by Product by Indication, by Route of Administration, by Distribution Channel and Regional Analysis, 2023-2030
出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
血栓溶解薬の世界市場、規模調査＆予測、製品別、適応症別、投与経路別、流通チャネル別、地域別分析、2023～2030年
出版日: 2023年10月20日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

血栓溶解薬の世界市場は、2022年に約286億米ドルと評価され、予測期間2023～2030年には8.2%以上の健全な成長率で成長すると予測されています。

血栓溶解薬は、緊急時に血栓を溶解するために使用される薬薬です。これらの薬薬は、線溶として知られる体内の自然な血栓溶解システムを活性化し、血栓を形成するフィブリン網目構造を破壊することによって作用します。最も使用されている血栓溶解薬は、組織プラスミノーゲンアクチベーター（tPA）であり、アルテプラーゼとも呼ばれます。tPAは体内に自然に存在するタンパク質で、血栓の溶解を助ける。血栓溶解薬市場が拡大している背景には、血栓性疾患の新興国市場の増加や、血栓溶解薬の開発に対する政府の取り組みや資金援助などの要因があります。

心血管疾患、深部静脈血栓症、肺塞栓症、虚血性脳卒中の有病率の上昇により、血栓溶解薬の需要が増加しています。これらの疾患では、血栓を溶解して血流を回復させるための早急な治療が必要であり、それによって市場の成長が促進されています。2022年に発表されたGlobal Stroke Factsheetによると、脳卒中の発症リスクは過去17年間で50%増加しており、2022年現在、4人に1人が生涯に脳卒中を発症すると推定されています。さらに、世界保健機関（WHO）の報告書（2020年）によると、世界中で毎年約1,790万人が心臓疾患に苦しんでいます。このように、心血管疾患や虚血性脳卒中などの血栓性疾患の有病率の上昇が、市場成長の原動力となっています。さらに、血栓を破壊する薬物療法の進歩、血栓障害に対する認識と診断の高まりが、市場成長の有利な機会を生み出しています。しかし、血栓溶解薬の高価格とインターベンション治療の進歩は、2023～2030年の予測期間を通じて市場成長を阻害します。

血栓溶解薬の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、主要市場参入企業の優位性、疾患有病率の増加、研究開発活動の増加により、2022年の市場を独占しました。アジア太平洋は、高齢者の増加、新興国市場の増加、製品開拓のための共同研究数の増加、市場参入における政府機関や民間機関の積極的な参加などの要因により、予測期間中に大きく成長すると予想されます。

本調査の目的は、近年における様々なセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面の両方を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。

目次

第1章 エグゼクティブサマリー

第2章 血栓溶解薬の世界市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 血栓溶解薬の世界市場力学

  • 血栓溶解薬市場の影響分析（2020年～2030年）
    • 市場促進要因
      • 血栓性疾患の発生率の増加
      • 血栓溶解薬の開発に対する政府の取り組みと資金援助
    • 市場の課題
      • 血栓溶解薬の高コスト

第3章 インターベンション手技の進歩

    • 市場機会
      • 血栓溶解薬治療の進歩
      • 血栓症に対する認識と診断の高まり

第4章 世界の血栓溶解薬市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 血栓溶解薬の世界市場：製品別

  • 市場スナップショット
  • 血栓溶解薬の世界市場：製品別、実績・ポテンシャル分析
  • 血栓溶解薬の世界市場：製品別、推定・予測、2020～2030年
  • 血栓溶解薬市場、サブセグメント別分析
    • 血栓溶解薬
    • 抗血小板薬
    • 抗凝固薬
    • その他

第6章 血栓溶解薬の世界市場：適応症別

  • 市場スナップショット
  • 血栓溶解薬の世界市場：適応症別、実績・ポテンシャル分析
  • 血栓溶解薬の世界市場：適応症別、推定・予測、2020～2030年
  • 血栓溶解薬市場、サブセグメント分析
    • 深部静脈血栓症
    • 心房細動
    • 肺塞栓症
    • その他

第7章 血栓溶解薬の世界市場：投与経路別

  • 市場スナップショット
  • 血栓溶解薬の世界市場：投与ルート別、実績・ポテンシャル分析
  • 血栓溶解薬の世界市場、投与ルート別、推定・予測、2020～2030年
  • 血栓溶解薬市場、サブセグメント分析
    • 経口薬
    • 注射薬

第8章 血栓溶解薬の世界市場：流通経路別

  • 市場スナップショット
  • 血栓溶解薬の世界市場：流通チャネル別、実績・ポテンシャル分析
  • 血栓溶解薬の世界市場：流通チャネル別、推定・予測、2020～2030年
  • 血栓溶解薬市場、サブセグメント分析
    • 病院薬局
    • ドラッグストア
    • オンライン薬局
    • 小売薬局

第9章 血栓溶解薬の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 血栓溶解薬市場の地域別市場スナップショット
  • 北米
    • 米国
      • 製品、推定・予測、2020～2030年
      • 適応症、推定・予測、2020～2030年
      • 投与経路、推定・予測、2020～2030年
      • 流通チャネル、推定・予測、2020～2030年
    • カナダ
  • 欧州の血栓溶解薬市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • アジア太平洋の血栓溶解薬市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他のアジア太平洋
  • ラテンアメリカの血栓溶解薬市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他の中東およびアフリカ

第10章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Bayer AG
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
    • Merck & Co
    • Sun Pharmaceutical Industries Ltd.
    • Johnson & Johnson Services Inc
    • Sanofi-Aventis S.A
    • Boehringer Ingelheim Gmbh
    • Dr. Reddy's Laboratories
    • Genentech Inc.
    • Pfizer Inc.
    • Eli Lilly and Company

第11章 調査プロセス

  • 調査プロセス
    • データ鉱業
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Clot Busting Drugs Market, report scope
  • TABLE 2. Global Clot Busting Drugs Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Clot Busting Drugs Market estimates & forecasts by Product 2020-2030 (USD Billion)
  • TABLE 4. Global Clot Busting Drugs Market estimates & forecasts by Indication 2020-2030 (USD Billion)
  • TABLE 5. Global Clot Busting Drugs Market estimates & forecasts by Route of Administration 2020-2030 (USD Billion)
  • TABLE 6. Global Clot Busting Drugs Market estimates & forecasts by Distribution Channel 2020-2030 (USD Billion)
  • TABLE 7. Global Clot Busting Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Clot Busting Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Clot Busting Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Clot Busting Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Clot Busting Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Clot Busting Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Clot Busting Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. Global Clot Busting Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. Global Clot Busting Drugs Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 16. Global Clot Busting Drugs Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 17. U.S. Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. U.S. Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. U.S. Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. Canada Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21. Canada Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. Canada Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. UK Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24. UK Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. UK Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. Germany Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27. Germany Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. Germany Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. France Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30. France Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. France Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Italy Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33. Italy Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Italy Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. Spain Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36. Spain Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. Spain Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. RoE Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39. RoE Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. RoE Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. China Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42. China Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. China Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. India Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45. India Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. India Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. Japan Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48. Japan Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. Japan Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. South Korea Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51. South Korea Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. South Korea Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. Australia Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54. Australia Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. Australia Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. RoAPAC Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57. RoAPAC Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. RoAPAC Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Brazil Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60. Brazil Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Brazil Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. Mexico Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63. Mexico Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. Mexico Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. RoLA Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66. RoLA Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoLA Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. Saudi Arabia Clot Busting Drugs Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 69. South Africa Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 70. RoMEA Clot Busting Drugs Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 71. List of secondary sources, used in the study of global Clot Busting Drugs Market
  • TABLE 72. List of primary sources, used in the study of global Clot Busting Drugs Market
  • TABLE 73. Years considered for the study
  • TABLE 74. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverabl

LIST OF FIGURES

  • FIG 1. Global Clot Busting Drugs Market, research methodology
  • FIG 2. Global Clot Busting Drugs Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Clot Busting Drugs Market, key trends 2022
  • FIG 5. Global Clot Busting Drugs Market, growth prospects 2023-2030
  • FIG 6. Global Clot Busting Drugs Market, porters 5 force model
  • FIG 7. Global Clot Busting Drugs Market, pest analysis
  • FIG 8. Global Clot Busting Drugs Market, value chain analysis
  • FIG 9. Global Clot Busting Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Clot Busting Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Clot Busting Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Clot Busting Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Clot Busting Drugs Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Clot Busting Drugs Market, regional snapshot 2020 & 2030
  • FIG 15. North America Clot Busting Drugs Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Clot Busting Drugs Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Clot Busting Drugs Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Clot Busting Drugs Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Clot Busting Drugs Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Clot Busting Drugs Market is valued at approximately USD 28.6 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.2% over the forecast period 2023-2030. Clot-busting drugs are medications used to dissolve blood clots in a medical emergency. These drugs work by activating the body's natural clot-dissolving system, known as fibrinolysis, to break down the fibrin meshwork that forms blood clots. The most used clot-busting drug is tissue plasminogen activator (tPA), also called alteplase. tPA is a naturally occurring protein in the body that helps dissolve blood clots. The Clot Busting Drugs market is expanding because of factors such as the increasing incidence of thrombotic disorders and government initiatives and funding for the development of thrombolytic drugs.

The rising prevalence of cardiovascular diseases, deep vein thrombosis, pulmonary embolism, and ischemic stroke has led to an increased demand for clot-busting drugs. These conditions require immediate treatment to dissolve blood clots and restore blood flow, thereby driving market growth. The Global Stroke Factsheet released in 2022 reveals that the risk for developing stroke has increased by 50% over the last 17 years and as of year 2022, 1 in 4 people is estimated to have a stroke in their lifetime. Furthermore, according to World Health Organization Report 2020 around 17.9 million lives each year are being suffered from heart disorders across the globe. Thus rising prevalence of thrombotic disorders such as cardiovascular diseases and ischemic stroke is driving the market growth. In addition, advancements in clot-busting drug therapies and rising awareness and diagnosis of clotting disorders are creating a lucrative opportunity for market growth. However, the high cost of Clot Busting Drugs and advancements in interventional procedures: stifles market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Clot Busting Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, increasing disease prevalence, and a rising number of research and development activities. Asia Pacific is expected to grow significantly during the forecast period, owing to factors such as the rising geriatric, increasing prevalence of diseases, an increase in the number of collaborations for product development, and active participation of government and private organizations in the market space.

Major market players included in this report are:

  • Bayer AG
  • Merck & Co
  • Sun Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services Inc
  • Sanofi-Aventis S.A
  • Boehringer Ingelheim Gmbh
  • Dr. Reddy's Laboratories
  • Genentech Inc.
  • Pfizer Inc.
  • Eli Lilly and Company

Recent Developments in the Market:

  • In December 2021, The U.S. FDA approved XARELTO (rivaroxaban), an oral anticoagulant manufactured by Janssen Pharmaceutical. The medication has two pediatric indications, including the prevention of deep vein thrombosis (DVT) that causes pulmonary embolism.
  • In June 2021, Boehringer Ingelheim released dabigatran etexilate, the active ingredient in Pradaxa. Pradaxa oral pellets were given FDA approval to treat venous thromboembolism, a condition in which blood clots develop in the veins, in children three months to under twelve years old.

Global Clot Busting Drugs Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Product, Indication, Route of Administration, Distribution Channel, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:

  • Thrombolytic Drugs
  • Anti-Platelet Drugs
  • Anticoagulants
  • Others

By Indication:

  • Deep Vein Thrombosis
  • Atrial Fibrillation
  • Pulmonary Embolism
  • Others

By Route of Administration:

  • Oral
  • Injectable

By Distribution Channel:

  • Hospital Pharmacy
  • Drug Store
  • Online Pharmacy
  • Retail Pharmacy

By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • ROE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Clot Busting Drugs Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Clot Busting Drugs Market, by Product, 2020-2030 (USD Billion)
    • 1.2.3. Clot Busting Drugs Market, by Indication, 2020-2030 (USD Billion)
    • 1.2.4. Clot Busting Drugs Market, by Route of Administration, 2020-2030 (USD Billion)
    • 1.2.5. Clot Busting Drugs Market, by Distribution Channel, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Clot Busting Drugs Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Clot Busting Drugs Market Dynamics

  • 3.1. Clot Busting Drugs Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing incidence of thrombotic disorders
      • 3.1.1.2. Government initiatives and funding for the development of thrombolytic drugs
    • 3.1.2. Market Challenges
      • 3.1.2.1. High Cost of Clot-Busting Drugs

3.1.2.2. Advancements in interventional procedures:

    • 3.1.3. Market Opportunities
      • 3.1.3.1. Advancements in clot-busting drug therapies
      • 3.1.3.2. Rising awareness and diagnosis of clotting disorders

Chapter 4. Global Clot Busting Drugs Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Clot Busting Drugs Market, by Product

  • 5.1. Market Snapshot
  • 5.2. Global Clot Busting Drugs Market by Product, Performance - Potential Analysis
  • 5.3. Global Clot Busting Drugs Market Estimates & Forecasts by Product 2020-2030 (USD Billion)
  • 5.4. Clot Busting Drugs Market, Sub Segment Analysis
    • 5.4.1. Thrombolytic Drugs
    • 5.4.2. Anti-Platelet Drugs
    • 5.4.3. Anticoagulants
    • 5.4.4. Others

Chapter 6. Global Clot Busting Drugs Market, by Indication

  • 6.1. Market Snapshot
  • 6.2. Global Clot Busting Drugs Market by Indication, Performance - Potential Analysis
  • 6.3. Global Clot Busting Drugs Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
  • 6.4. Clot Busting Drugs Market, Sub Segment Analysis
    • 6.4.1. Deep Vein Thrombosis
    • 6.4.2. Atrial Fibrillation
    • 6.4.3. Pulmonary Embolism
    • 6.4.4. Others

Chapter 7. Global Clot Busting Drugs Market, by Route of Administration

  • 7.1. Market Snapshot
  • 7.2. Global Clot Busting Drugs Market by Route of Administration, Performance - Potential Analysis
  • 7.3. Global Clot Busting Drugs Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
  • 7.4. Clot Busting Drugs Market, Sub Segment Analysis
    • 7.4.1. Oral
    • 7.4.2. Injectable

Chapter 8. Global Clot Busting Drugs Market, by Distribution Channel

  • 8.1. Market Snapshot
  • 8.2. Global Clot Busting Drugs Market by Distribution Channel, Performance - Potential Analysis
  • 8.3. Global Clot Busting Drugs Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
  • 8.4. Clot Busting Drugs Market, Sub Segment Analysis
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Drug Store
    • 8.4.3. Online Pharmacy
    • 8.4.4. Retail Pharmacy

Chapter 9. Global Clot Busting Drugs Market, Regional Analysis

  • 9.1. Top Leading Countries
  • 9.2. Top Emerging Countries
  • 9.3. Clot Busting Drugs Market, Regional Market Snapshot
  • 9.4. North America Clot Busting Drugs Market
    • 9.4.1. U.S. Clot Busting Drugs Market
      • 9.4.1.1. Product breakdown estimates & forecasts, 2020-2030
      • 9.4.1.2. Indication breakdown estimates & forecasts, 2020-2030
      • 9.4.1.3. Route of Administration breakdown estimates & forecasts, 2020-2030
      • 9.4.1.4. Distribution Channel breakdown estimates & forecasts, 2020-2030
    • 9.4.2. Canada Clot Busting Drugs Market
  • 9.5. Europe Clot Busting Drugs Market Snapshot
    • 9.5.1. U.K. Clot Busting Drugs Market
    • 9.5.2. Germany Clot Busting Drugs Market
    • 9.5.3. France Clot Busting Drugs Market
    • 9.5.4. Spain Clot Busting Drugs Market
    • 9.5.5. Italy Clot Busting Drugs Market
    • 9.5.6. Rest of Europe Clot Busting Drugs Market
  • 9.6. Asia-Pacific Clot Busting Drugs Market Snapshot
    • 9.6.1. China Clot Busting Drugs Market
    • 9.6.2. India Clot Busting Drugs Market
    • 9.6.3. Japan Clot Busting Drugs Market
    • 9.6.4. Australia Clot Busting Drugs Market
    • 9.6.5. South Korea Clot Busting Drugs Market
    • 9.6.6. Rest of Asia Pacific Clot Busting Drugs Market
  • 9.7. Latin America Clot Busting Drugs Market Snapshot
    • 9.7.1. Brazil Clot Busting Drugs Market
    • 9.7.2. Mexico Clot Busting Drugs Market
  • 9.8. Middle East & Africa Clot Busting Drugs Market
    • 9.8.1. Saudi Arabia Clot Busting Drugs Market
    • 9.8.2. South Africa Clot Busting Drugs Market
    • 9.8.3. Rest of Middle East & Africa Clot Busting Drugs Market

Chapter 10. Competitive Intelligence

  • 10.1. Key Company SWOT Analysis
    • 10.1.1. Company 1
    • 10.1.2. Company 2
    • 10.1.3. Company 3
  • 10.2. Top Market Strategies
  • 10.3. Company Profiles
    • 10.3.1. Bayer AG
      • 10.3.1.1. Key Information
      • 10.3.1.2. Overview
      • 10.3.1.3. Financial (Subject to Data Availability)
      • 10.3.1.4. Product Summary
      • 10.3.1.5. Recent Developments
    • 10.3.2. Merck & Co
    • 10.3.3. Sun Pharmaceutical Industries Ltd.
    • 10.3.4. Johnson & Johnson Services Inc
    • 10.3.5. Sanofi-Aventis S.A
    • 10.3.6. Boehringer Ingelheim Gmbh
    • 10.3.7. Dr. Reddy's Laboratories
    • 10.3.8. Genentech Inc.
    • 10.3.9. Pfizer Inc.
    • 10.3.10. Eli Lilly and Company

Chapter 11. Research Process

  • 11.1. Research Process
    • 11.1.1. Data Mining
    • 11.1.2. Analysis
    • 11.1.3. Market Estimation
    • 11.1.4. Validation
    • 11.1.5. Publishing
  • 11.2. Research Attributes
  • 11.3. Research Assumption